Andrew Bellinger - Jun 16, 2021 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Scientific Officer
Signature
/s/ Andrew Ashe, Attorney-in-Fact
Stock symbol
VERV
Transactions as of
Jun 16, 2021
Transactions value $
$0
Form type
3
Date filed
6/16/2021, 07:34 PM
Next filing
Jun 21, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 108K $8.24 Direct F1
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 216K $2.87 Direct F2
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 43.2K $1.48 Direct F3
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 162K $1.48 Direct F4
holding VERV Stock Option (right to buy) Jun 16, 2021 Common Stock 21.6K $1.39 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on February 12, 2021 for 107,997 shares. 25% of the shares underlying the option will vest on February 1, 2022, and the remainder are scheduled to vest in equal monthly installments thereafter until February 1, 2025.
F2 The option was granted on September 16, 2020 for 215,994 shares. 25% of the shares underlying the option will vest on September 16, 2021, and the remainder are scheduled to vest in equal monthly installments thereafter until September 16, 2024.
F3 The option was granted on September 17, 2019 for 43,198 shares. 25% of the shares underlying the option vested on October 1, 2020, and the remainder are scheduled to vest in equal monthly installments thereafter until October 1, 2023.
F4 The option was granted on September 17, 2019 for 161,995 shares. The shares underlying the option vest in equal monthly installments until October 1, 2023.
F5 The option was granted on June 25, 2019 for 21,599 shares. The shares underlying the option vested on April 1, 2020.

Remarks:

Exhibit Index: 24.1 Power of Attorney